DUBLIN–(BUSINESS WIRE)–The “Hematopoietic Progenitor Kinase 1 Inhibitors – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Hematopoietic progenitor kinase 1 inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Players
- Treadwell Therapeutics
- BeiGene
- Nimbus Therapeutics
- Blueprint Medicines
- RAPT Therapeutics
- Ryvu Therapeutics
- Arvinas
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Hematopoietic progenitor kinase 1 inhibitors R&D. The therapies under development are focused on novel approaches for Hematopoietic progenitor kinase 1 inhibitors.
Hematopoietic progenitor kinase 1 inhibitors Emerging Drugs Chapters
This segment of the Hematopoietic progenitor kinase 1 inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Hematopoietic progenitor kinase 1 inhibitors Emerging Drugs
CFI-40241: Treadwell Therapeutics
CFI-402411 is a novel, highly orally available immunomodulatory small molecule inhibitor of HPK1 (Hematopoietic Progenitor Kinase 1), a critical regulator of immune cell activation, antigen presentation, and T cell responses to immunosuppressive factors. CFI-402411 has the potential to be an effective treatment in a wide range of cancers as a monotherapy, and in combination with other agents including checkpoint inhibitors.
BGB-15025: Beigene
BGB-15025 is an investigational hematopoietic progenitor kinase 1 (HPK1) inhibitor discovered and being developed by BeiGene. HPK1 is a key negative feedback regulator of T-cell receptor signaling, which is believed to play a key role in antitumor immune response. In preclinical studies, the inhibition of HPK1 enhanced T-cell activation, which is expected to enhance the anti-tumor activity of anti-PD-1 inhibitors such as BeiGene’s tislelizumab.
Hematopoietic progenitor kinase 1 inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Hematopoietic progenitor kinase 1 inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Major Players working on Hematopoietic progenitor kinase 1 inhibitors
There are approx. 6+ key companies which are developing the Hematopoietic progenitor kinase 1 inhibitors. The companies which have their Hematopoietic progenitor kinase 1 inhibitors drug candidates in the most advanced stage, i.e. Phase I/II include, Treadwell Therapeutics.
Phases
This report covers around 6+ products under different phases of clinical development like
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Hematopoietic progenitor kinase 1 inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Hematopoietic progenitor kinase 1 inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Hematopoietic progenitor kinase 1 inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hematopoietic progenitor kinase 1 inhibitors drugs.
Hematopoietic progenitor kinase 1 inhibitors Report Insights
- Hematopoietic progenitor kinase 1 inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Hematopoietic progenitor kinase 1 inhibitors Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Scenario and Emerging Therapies:
- How many companies are developing Hematopoietic progenitor kinase 1 inhibitors drugs?
- How many Hematopoietic progenitor kinase 1 inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hematopoietic progenitor kinase 1 inhibitors?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Hematopoietic progenitor kinase 1 inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Hematopoietic progenitor kinase 1 inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/e02ajh
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900